COVID-19: Vaccines and Therapeutics
The Centers for Disease Control and Prevention early Friday morning opted for a broad endorsement of Pfizer COVID-19 vaccine booster shots, issuing interim guidance that recommends boosters for many vaccinated individuals, including those in high-risk occupational and institutional settings.
Colorado mom of a two-year old hospitalized for COVID-19 encourages people to get vaccinated 鈥渇or our young children who can鈥檛.鈥
Leaders of children鈥檚 hospitals applaud expanded vaccine eligibility among kids as an important step toward ending the pandemic.
The FDA and CDC鈥檚 recent booster shot policy decisions are important steps toward ending COVID-19. The FDA and CDC鈥檚 review further confirms the safety and efficacy of the COVID-19 vaccines, and underscores why hospitals and health systems have worked so hard to vaccinate their staff and鈥
In a study of more than 4,900 health care workers across 33 sites in 25 U.S. states, the Pfizer and Moderna COVID-19 vaccines were 89% and 96% effective, respectively, at preventing symptomatic COVID-19 infections in fully vaccinated workers, according to final results reported yesterday in the New鈥
In AHA鈥檚 newest #MyWhy video, nine hospital employees from UAB Medicine in Alabama candidly discuss their COVID-19 vaccine experience, starting with initial hesitancies and navigating misinformation surrounding the vaccine鈥檚 development and rumored side effects.
The Centers for Medicare & Medicaid Services yesterday began publicly sharing COVID-19 vaccination rates for nursing home staff and residents on its Care Compare website.
Johnson & Johnson said its phase 3 trial data confirms its vaccine鈥檚 durability and provided evidence of a second, booster shot鈥檚 effectiveness against COVID-19.
The Food and Drug Administration authorized administering the monoclonal antibodies bamlanivimab and etesevimab together to prevent COVID-19 in certain children and adults exposed to SARS-CoV-2 who are not fully vaccinated against COVID-19 and at high-risk for progressing to severe disease.
Pfizer released the first data evaluating a COVID-19 vaccine鈥檚 safety and effectiveness for children between the ages of 5 and 11.